From Darkness to Light With Biomarkers in Early Clinical Trials of Cancer Drugs

被引：27

作者：

Carden, C. P. ^{[1
,2
]}

Banerji, U. ^{[1
,2
]}

Kaye, S. B. ^{[1
,2
]}

Workman, P. ^{[1
,2
]}

de Bono, J. S. ^{[1
,2
]}

机构：

[1] Royal Marsden Natl Hlth Serv Fdn Trust, Surrey, England

[2] Inst Canc Res, Surrey, England

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2009年 / 85卷 / 02期

关键词：

RESISTANT PROSTATE-CANCER; MALIGNANCIES; INHIBITOR; CELLS;

D O I：

10.1038/clpt.2008.223

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Compared with conventional chemotherapy, rationally designed molecularly targeted agents may be more likely to have antitumor activity in selected tumor subgroups driven by the oncogenic signals targeted by these compounds and a different side-effect profile. The use of biomarkers in the early clinical trials of these new anticancer agents has the potential to increase study participants' benefit from early clinical trials, accelerate the drug development process, maximize the ability to generate important biological information about human cancer, and decrease the risk of late and costly drug attrition.

引用

页码：131 / 133

页数：3

共 14 条

[1] Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven [J].

Attard, Gerhardt ;

Reid, Alison H. M. ;

Yap, Timothy A. ;

Raynaud, Florence ;

Dowsett, Mitch ;

Settatree, Sarah ;

Barrett, Mary ;

Parker, Christopher ;

Martins, Vanessa ;

Folkerd, Elizabeth ;

Clark, Jeremy ;

Cooper, Colin S. ;

Kaye, Stan B. ;

Dearnaley, David ;

Lee, Gloria ;

de Bono, Johann S. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (28) :4563-4571

[2] Phase I pharmacokinetic and pharmacodynarnic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies [J].

Banerji, U ;

O'Donnell, A ;

Scurr, M ;

Pacey, S ;

Stapleton, S ;

Asad, Y ;

Simmons, L ;

Maloney, A ;

Raynaud, F ;

Campbell, M ;

Walton, M ;

Lakhani, S ;

Kaye, S ;

Workman, P ;

Judson, I .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (18) :4152-4161

[3] Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer [J].

de Bono, Johann S. ;

Scher, Howard I. ;

Montgomery, R. Bruce ;

Parker, Christopher ;

Miller, M. Craig ;

Tissing, Henk ;

Doyle, Gerald V. ;

Terstappen, Leon W. W. M. ;

Pienta, Kenneth J. ;

Raghavan, Derek .

CLINICAL CANCER RESEARCH, 2008, 14 (19) :6302-6309

[4] Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy [J].

Farmer, H ;

McCabe, N ;

Lord, CJ ;

Tutt, ANJ ;

Johnson, DA ;

Richardson, TB ;

Santarosa, M ;

Dillon, KJ ;

Hickson, I ;

Knights, C ;

Martin, NMB ;

Jackson, SP ;

Smith, GCM ;

Ashworth, A .

NATURE, 2005, 434 (7035) :917-921

[5]

FONG P, 2008, J CLIN ONCOL, V26, P1

[6] Signaling networks assembled by oncogenic EGFR and c-Met [J].

Guo, Ailan ;

Villen, Judit ;

Kornhauser, Jon ;

Lee, Kimberly A. ;

Stokes, Matthew P. ;

Rikova, Klarisa ;

Possemato, Anthony ;

Nardone, Julie ;

Innocenti, Gregory ;

Wetzel, Randall ;

Wang, Yi ;

MacNeill, Joan ;

Mitchell, Jeffrey ;

Gygi, Steven P. ;

Rush, John ;

Polakiewicz, Roberto D. ;

Comb, Michael J. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (02) :692-697

[7] Opinion - Why is cancer drug discovery so difficult? [J].

Kamb, Alexander ;

Wee, Susan ;

Lengauer, Christoph .

NATURE REVIEWS DRUG DISCOVERY, 2007, 6 (02) :115-120

[8]

OLMOS D, 2008, ANN ONCOL

[9] Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies [J].

Orlowski, RZ ;

Stinchcombe, TE ;

Mitchell, BS ;

Shea, TC ;

Baldwin, AS ;

Stahl, S ;

Adams, J ;

Esseltine, DL ;

Elliott, PJ ;

Pien, CS ;

Guerciolini, R ;

Anderson, JK ;

Depcik-Smith, ND ;

Bhagat, R ;

Lehman, MJ ;

Novick, SC ;

O'Connor, OA ;

Soignet, SL .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (22) :4420-4427

[10] Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma [J].

Rothenberg, ML ;

LaFleur, B ;

Levy, DE ;

Washington, MK ;

Morgan-Meadows, SL ;

Ramanathan, RK ;

Berlin, JD ;

Benson, AB ;

Coffey, RJ .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (36) :9265-9274

← 1 2 →